Research programme: phosphodiesterase IV inhibitors - Celltech/Merck

Drug Profile

Research programme: phosphodiesterase IV inhibitors - Celltech/Merck

Alternative Names: PDE4 inhibitors research programme - Celltech/Merck

Latest Information Update: 21 Sep 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celltech Group
  • Developer Celltech Group; Merck & Co
  • Class
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 29 Sep 2003 Merck & Co. has extended the development period of its phosphodiesterase-IV inhibitors collaboration with Celltech Group
  • 25 Apr 2003 Preclinical trials in Asthma (PO)
  • 25 Apr 2003 Preclinical trials in Chronic obstructive pulmonary disease (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top